TORONTO, May 20, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a psychedelics biotech company, is pleased to announce the appointment of Professor Matthew Macaluso, D.O. as a scientific and clinical advisor for PharmaTher’s clinical research programs involving ketamine as a potential treatment for major depressive disorders and…

Source

Previous articleMindMed Announces the Approval of Mescaline Study
Next articlePsychedelic Science 101: What are Psychedelic Drugs?